Dr. Erin Longbrake, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 71
Licensed in Connecticut since 2016, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Ohio State University College of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CT license 55076 (first issued 2016; active) · MO license 2013005295 -
Internal Medicine Physician
MO license 2013005295
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
- Greenwich Hospital Association - Greenwich, CT
Medical groups
- Yale University (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 71
- Services billed
- 197
- Patients’ average age
- 64
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 74 | 60 |
| Established patient office or other outpatient visit, 40-54 minutes | 34 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dalfampridine Er (dalfampridine) | 43 |
| Baclofen Other prescribers in North Haven, CT | 39 |
| Gabapentin Other prescribers in North Haven, CT | 36 |
| Kesimpta Pen (ofatumumab) | 17 |
| Pregabalin Other prescribers in North Haven, CT | 14 |
| Sumatriptan Succinate Other prescribers in North Haven, CT | 14 |
| Carbamazepine Er (carbamazepine) Other prescribers in North Haven, CT | 13 |
| Quetiapine Fumarate Other prescribers in North Haven, CT | 13 |
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in North Haven, CT | 12 |
| Glatiramer Acetate | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 19 payments worth $20,507 in total to this clinician.
| Genentech USA, Inc. | $7,638 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $3,550 |
| Genzyme Corporation | $2,809 |
| EMD Serono, Inc. | $2,780 |
| Tg Therapeutics, Inc. | $2,530 |
| Genentech, Inc. | $1,200 |
| Consulting Fee | $16,958 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $2,769 |
| Food and Beverage | $401 |
| Travel and Lodging | $380 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Jun 20, 2025 | Consulting Fee | $7,065 |
| Alexion Pharmaceuticals, Inc. Nov 5, 2025 | Consulting Fee SOLIRIS · Rare Disease | $2,840 |
| Genzyme Corporation Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,769 |
| Tg Therapeutics, Inc. Sep 24, 2025 | Consulting Fee BRIUMVI · Immunology | $2,363 |
| EMD Serono, Inc. Nov 25, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $1,390 |
| EMD Serono, Inc. Jul 14, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $1,390 |
| Genentech, Inc. Jul 30, 2025 | Consulting Fee Ocrevus · Immunology | $1,200 |
| Alexion Pharmaceuticals, Inc. Aug 4, 2025 | Consulting Fee SOLIRIS · Rare Disease | $710 |
| Genentech USA, Inc. Jun 20, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $278 |
| Genentech USA, Inc. Jun 20, 2025 | Travel and Lodging travel to Dallas, TX | $101 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $614,748 in research payments for these studies, mostly to the institutions running them.
- A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neuro…
E.r. Squibb & Sons, L.l.c. - A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neuro…
Celgene Corporation - Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141486 - Federated learning: The Impact of Persistence on clinical and social economic outcomes in Multiple sclerosis Treatments
F. Hoffmann-la Roche AG - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - An open-label, single-arm 4-year study to evaluate effectiveness and safety of ocrelizumab treatment in patients with progressive multiple sclerosis
Genentech, Inc. - First in human study RO7121932
Genentech, Inc. - Impact of B-cell Depletion
Genentech, Inc. - Real world safety profiles for individuals with long term MS immunotherapy use during the COVID 19 pandemic
Biogen, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.